PATENT CLAIM ANALYSIS

Application Number: 15754191
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-01
Patent Classification: ["514", "282000"]

Abstract:
The presently disclosed subject matter provides methods for inhibiting the growth and/or survival of bacteria from the  Borrelia  genus and for treating Lyme disease. These methods include agents that inhibit the glutathione/γ-glutamyl pathway and are involved in protection against free radical damage, cell membranes, energy production, and/or reactive oxygen species production. Many of these compounds are antimicrobial agents (antibiotics, antivirals, antifungals, anthelmintics or antiparasitics) and drugs used for treating other non-infectious conditions.

Claim (Index 9):
A method for treating Lyme disease in a patient in need thereof, the method comprising administering to a patient an effective amount of at least one agent selected from the group consisting of verteporfin, thonzonium bromide, tetrachloroethylene, benzododecinium chloride, butyl chloride (1-chlorobutane), 3-formyl rifamycin, potassium antimonyl tartrate (tartar emetic), toltrazuril, thiostrepton, pyroglutamic acid, mepartricin, tilorone, oxantel, hycanthone, pyrimethamine, trilocarban (3,4,4\u2032-trichlorocarbanilide), carbenicillin, oltipraz, bitoscanate, sarafloxacin, bacitracin, dextrorphan tartrate, tetramisole, bifonazole, ethacridine lactate, zanamivir, aluminum lactate, p-arsanilic acid, nifursol, nevirapine, rifaximin, oxibendazole, metrifonate, indatraline, florfenicol, benznidazole, ganciclovir, tazobactam, oxfendazole, phenothiazine, flubendazole, midecamycin, fluconazole, docosanol, aztreonam, benzoylpas (4-Benzamido salicylic acid), trifluridine, undecylenic acid, closantel, cefixime, thiamphenicol, ricobendazole (albendazole oxide), sulfamoxole, clopidol, tosufloxacin, metampicillin, amikacin, lamivudine, cephalosporin C, sulfachlorpyridazine, lomofungin, artesunate, valacyclovir, carzenide (4-carboxybenzenesulfonamide), clinafloxacin, efavirenz, cefsulodin, cloxyquin (5-chloro-8-hydroxy-quinoline), symclosene (trichloroisocyanuric acid), didanosine (2\u2032-3\u2032-dideoxyinosine), floxuridine (5-fluorodeoxyuridine), cyacetacide, roxithromycin, oxiconazole nitrate, climbazole, protionamide, ribavirin, griseofulvin, rifamycin SV, salicylanilide, diclazuril, imiquimod, penciclovir, nystatin, ampicillin, puromycin, stavudine (2\u2032,3\u2032-didehydro-3\u2032-deoxythymidine), potassium iodide, voriconazole, penimepicycline, amantadine, nitroxoline (8-hydroxy 5-nitroquinoline), 4-aminosalicylic acid, ciclopirox olamine, nelfinavir mesylate, anisomycin, betamipron (n-benzoyl-b-alanine), famciclovir, flucytosine (5-fluorocytosine), clotrimazole, rimantadine, pazufloxacin, carbadox, amantadine, dibekacin, clorsulon, thiacetazone (amithiozone), fleroxacin, clofoctol, butoconazole nitrate, quinaldine blue, and methylene blue.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.31746
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15799573', '15200657', '15539442', '15501469', '12676794']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6819378855944146
- 35 USC 102 Novelty (BERT): 0.503707736234147
- Combined Prediction Score: 0.6641148706583878
- Mean Citation Score: 165.459292
- Max Citation Score: 170.63629
- Similarity Product: 102.90449181818724

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test